Brief: FDA Approves Pembrolizumab Combination For Muscle Invasive Bladder Cancer
10/07/2026 15:28
BRIEF-FDA Approves Pembrolizumab Combination For Muscle Invasive Bladder Cancer July 10 (Reuters) - FDA:
FDA: APPROVES PEMBROLIZUMAB OR PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH EACH WITH ENFORTUMAB VEDOTIN-EJFV FOR MUSCLE INVASIVE BLADDER CANCER
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Astellas Pharma
See all newsBrief: Immuneering To Collaborate With Astellas On Clinical Studies Of Investigational CLDN18.2 Programs In Combination With Atebimetinib For Pancreatic Cancer Patients
Health Rounds: New blood test finds early risk for ovarian cancer
Health Rounds: New blood test finds early risk for ovarian cancer
Refile: Astellas employee imprisoned in China to be released in December, Japanese media report
Table: Astellas Pharma -6-MTH group results (IFRS)